Boundless Bio, Inc. (BOLD)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XPAR 
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know
Boundless Bio, Inc. (BOLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
January Effect Builds Up Momentum: 5 Small-Cap Stocks to Buy
After logging its worst month, the Russell 2000 Index is up 0.4% in the initial week of 2025, indicating that the "January Effect" is building up momentum.
Boundless Bio, Inc. (BOLD) Loses -19.52% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Boundless Bio, Inc. (BOLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -31.59% in 4 Weeks, Here's Why You Should You Buy the Dip in Boundless Bio, Inc. (BOLD)
Boundless Bio, Inc. (BOLD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
